AstraZeneca partner sticks with two full dose regimen in Covid trials in India
The British drugmaker has said its Covid-19 vaccine could be up to 90% effective if administered as a half dose followed by a full dose, but some scientists have questioned the robustness of that result because only a few thousand people were given that regimen in late-stage UK trials.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Biotechnology | COVID-19 | India Health | Pharmaceuticals | UK Health | Vaccines